SUMMARY The diagnostic significance of anti-double-stranded deoxyribonucleic acid (antidsDNA) determination was evaluated in a prospective manner from 1974 to 1982 in a group of 441 patients without systemic lupus erythematosus whose sera were found to contain antibodies to dsDNA on routine screening (Farr assay). Within one year 69% (304) of these patients fulfilled the preliminary American Rheumatism Association (ARA) criteria for systemic lupus erythematosus (SLE). Eighty-two of the remaining 137 patients were followed up for several years. At the end of the study 52% of these patients had also developed systemic lupus erythematosus. Patients who developed systemic lupus erythematosus were characterised by the occurrence of relatively high avidity anti-dsDNA in the circulation compared with patients who did not develop systemic lupus erythematosus. It can be concluded that about 85% of patients without systemic lupus erythematosus with anti-dsDNA in the circulation will develop SLE within a few years. Taking into account the relative avidity of anti-dsDNA, as determined by calculation of Farr/polyethylene glycol (PEG) ratios, we conclude that patients with relatively high avidity anti-dsDNA are more prone to develop systemic lupus erythematosus than patients with relatively low avidity anti-dsDNA.
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Antibodies to deoxyribonucleic acid (DNA) occupy a special position in the study of systemic lupus erythematosus (SLE). The appearance of antibodies to DNA has been alleged to predict exacerbations of disease,1 2 and the diagnostic importance of antidsDNA has recently been stressed by incorporation of its presence in serum as an ARA criterion.34
From early studies on DNA binding it was concluded that the Farr assay provides a sensitive and highly specific test for SLE.5 6On the other hand high values of anti-DNA have also been described in patients with chronic active hepatitis and Q fever endocarditis. anti-dsDNA assays has been carried out by testing panels of serum samples from selected patients with well defined clinical disease. In this way we have confirmed the specificity for SLE of anti-dsDNA measured by the Farr assay and by the immunofluorescence test (IFT) on Crithidia luciliae. However, when sera sent to us for routine diagnostic anti-dsDNA determination were tested, the specificity for SLE of both methods was completely lost. 8 We found antibodies to dsDNA in many patients who were not diagnosed as cases of SLE and did not fulfil the preliminary ARA criteria. The sera we tested came from patients suspected of having SLE, and were therefore negatively selected for actually having SLE; a major reason for sending the sera to us was to obtain further information and to establish a diagnosis. The finding of anti-dsDNA 245 in these non-SLE patients could be explained by the hypothesis that non-SLE patients with anti-dsDNA would develop SLE in the future, or that these patients formed a subset of SLE patients.
In order to evaluate the relevance of the presence of anti-dsDNA in non-SLE patients we performed a prospective study, from 1974 until 1982, in which all non-SLE patients with anti-dsDNA in their serum were followed up to see whether they would develop SLE or whether they had an SLE-like syndrome. Table 2 show that, apart from the group of patients who developed SLE in the first year after entering the study, there was a tendency either to develop SLE in the following three years, or not to do so. If the lost patients (n=55) are considered not to have developed SLE, then 26% of the patients studied had SLE after five years of follow-up study. If these 55 patients are left out, the conclusion is that 52% of the patients studied had SLE at that time. The cumulative results are depicted graphically in Fig. 1 . A steady increase in the percentage of SLE patients was seen during the first years. However, if a diagnosis of SLE was not reached after five years, 
then such a patient-albeit having raised titres of anti-dsDNA in the circulation -was not prone to develop SLE. At the end of our study 335 out of the 386 anti-dsDNA positive, non-SLE patients we followed had developed SLE (i.e. 87%), mostly during the first year after entering the study (Fig. 2) Fig. 4 initial anti-dsDNA levels of all patients followed for more than one year are depicted. In 1974 1975 1976 1977 1978 1979 1980 Fig. 4 Initial anti-dsDNA levels ofthe anti-dsDNA positive, non-SLE patients followed for more than one year. O= Patients who had not developed SLE at the end ofthe study. A = Patients who developed SLE during the study.
group I a mean anti-dsDNA level of 224 U/ml (SD 297) was found and in group II a mean value of 124 U/ml (SD 300). Statistical calculations did not show any correlation between the development of SLE and initial anti-dsDNA values.
Discussion
According to the revised ARA criteria for SLE4 the detection of antibodies to dsDNA can support the diagnosis of SLE. Since in the study presented here we sought to establish the relevance of anti-dsDNA determination in the diagnosis of SLE. we used the preliminary ARA criteria to differentiate between SLE and non-SLE in order to exclude anti-dsDNA positivity as a criterion for SLE.
During the period 1974-82 we studied 441 patients with serum antibodies to dsDNA who were not diagnosed as having SLE at the time. Nearly 70% of these non-SLE patients with anti-dsDNA in the circulation fulfilled the preliminary ARA criteria within one year after they were admitted to the follow-up study. After five years 52% of the 137 remaining patients had also developed SLE. The figure of 52% may be an overestimation, since 55 patients were lost during the study. If the presumption is made that all of these patients did not develop SLE, then a figure of 26% is obtained. On the other hand the possibility that 52% of these 'lost' patients also developed SLE cannot be excluded. If this were the case, then nearly 80% of the 137 non-SLE patients would have developed SLE after five years.
With the revised criteria for SLE another 20 patients would be confined to the SLE group at the end of the study. This would mean that over 70% of the patients who did not have SLE within the first year developed SLE during the five years of follow up study. All our patients were selected on the basis of anti-dsDNA and ANA positivity. As anti-dsDNA and ANAs go hand in hand in these cases, it will -in our view -be an overestimation of the value of these serological findings if both are used as separate criteria for SLE. We think that the diagnosis SLE should be made with caution because of future implications, for example the therapy required and, also the socioeconomic problems which may be raised, e.g., life insurance. With the revised criteria a patient with a quite good prognosis (e.g. mouth ulcers and slight skin rashes combined with a positive ANA test and a positive anti-dsDNA test) may be diagnosed as having SLE.
Our study shows that if anti-dsDNA is detected in a patient (by the Farr assay) the diagnosis SLEaccording to the preliminary ARA criteria -can in most cases be made within one year. The remaining patients can be divided into two groups: those who No clear difference between the initially detected anti-dsDNA levels of the two groups was observed (group I: 224 U/ml (SD 297); group II: 124 U/ml (SD 300)) as illustrated in Fi; 4. This is in accord with our previous findings and confirms the absence of a correlation between anti-dsDNA level and disease symptoms or activity. The same study also showed that there is no relation between (initial) anti-dsDNA level and prognosis of disease. It is noteworthy that anti-dsDNA levels of group II patients generally remained stable throughout the follow-up study; in only 20% of the patients were anti-dsDNA levels decreased or negative at the end of the study. Patients who developed SLE within the first year after initial anti-dsDNA detection could not be distinguished from group I patients either on the basis of the first signs of disease (ARA criteria 7 and 8) or on the basis of sex, age, duration of complaints before the exacerbation, or type of exacerbation. All patients who developed SLE are still being studied, and data on survival rates are being accumulated.
In conclusion we have found that 69% of a group of 441 non-SLE patients with anti-dsDNA in the circulation developed SLE within one year. Of the remaining patients 53% developed SLE within five years of the follow-up study. Excluding the 55 patients who were lost during follow up, we followed a total of 386 patients during this prospective study. At the end of the study 331 patients (87%) had SLE, which confirms the significance of anti-dsDNA determination. We support the incorporation of anti-dsDNA as an ARA criterion but would emphasise that the method employed for detection is crucial. Data presented in this paper clearly indicate that patients having high avidity anti-dsDNA in the circulation are more prone to develop SLE than patients with low avidity antidsDNA. The IFT on Crithidia luciliae and the PEG assay also detect anti-dsDNA of low avidity and have indeed been found to be less specific for SLE than the Farr assay which was used throughout this study.7 16 Therefore the effective incorporation of anti-dsDNA in the criteria for SLE requires that the detection method is selective for high avidity antidsDNA. As contamination of the DNA preparation with single-stranded regions also leads to a decrease in specificity of the assay for SLE,9 "' care should be taken that the antigen preparation used consists of entirely double-stranded DNA. Longitudinal studies of patients having only anti-dsDNA of low avidity are in progress and will be published at a later date. 
